MRK logo

Merck & Co., Inc.

MRK
Healthcare|Drug Manufacturers - General|US
$146.71
-0.23 (-0.16%)
DCF Value
$180.27
Graham Number
$20.09
Cash / Share
$3.89

Financials

Financial Snapshot

Market Cap
$361.96B
Enterprise Value
$406.19B
Revenue (TTM)
$67.30B
Net Income (TTM)
$2.45B
Cash & Investments
$9.65B
Net Cash
-$44.13B
Free Cash Flow (TTM)
$14.75B
Operating CF (TTM)
$18.70B
Debt/Equity
1.20

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$14.34B$8.50B$8.86B$10.45B$8.05B$8.10B$13.19B$7.09B$13.69B$14.56B$9.65B
Operating Cash Flow
$10.38B$6.45B$10.92B$13.44B$10.25B$14.11B$19.09B$13.01B$21.47B$16.47B$18.70B
Free Cash Flow
$8.76B$4.56B$8.31B$9.97B$5.82B$9.66B$14.71B$9.14B$18.10B$12.36B$14.75B
Capital Expenditure
-$1.61B-$1.89B-$2.62B-$3.47B-$4.43B-$4.45B-$4.39B-$3.86B-$3.37B-$4.11B-$3.96B
Financing Cash Flow
-$9.04B-$10.01B-$13.16B-$8.86B-$2.83B$2.59B-$9.12B-$4.81B-$7.03B-$1.92B$1.10B

R&D Spending

R&D (TTM)
$29.33B
R&D Intensity
43.6%
R&D Growth vs Prior
+134.4%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$39.81B$40.12B$42.29B$39.12B$41.52B$48.70B$59.28B$60.12B$64.17B$64.93B$67.30B
R&D Expense
$10.26B$10.34B$9.75B$9.72B$13.40B$12.24B$13.55B$30.53B$17.94B$12.51B$29.33B
R&D % of Revenue
25.8%25.8%23.1%24.9%32.3%25.1%22.9%50.8%28.0%19.3%43.6%
SG&A
$10.02B$10.07B$10.10B$9.46B$8.57B$9.40B$9.67B$9.88B$10.10B$10.73B$11.28B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$39.81B$40.12B$42.29B$39.12B$41.52B$48.70B$59.28B$60.12B$64.17B$64.93B$67.30B
Cost of Revenue
$14.03B$12.91B$13.51B$12.02B$13.62B$13.63B$17.41B$16.13B$15.19B$18.20B$15.51B
Gross Profit
$25.78B$27.21B$28.79B$27.11B$27.90B$35.08B$41.87B$43.99B$48.98B$46.73B$51.79B
R&D
$10.26B$10.34B$9.75B$9.72B$13.40B$12.24B$13.55B$30.53B$17.94B$12.51B$29.33B
SG&A
$10.02B$10.07B$10.10B$9.46B$8.57B$9.40B$9.67B$9.88B$10.10B$10.73B$11.28B
Operating Income
$5.50B$6.80B$8.93B$7.93B$5.55B$13.20B$18.28B$2.95B$20.22B$23.49B$10.93B
Interest Expense
$693.0M$754.0M$772.0M$893.0M$831.0M$806.0M$962.0M$1.15B$1.27B$1.36B$936.0M
Pretax Income
$4.66B$6.52B$8.70B$7.17B$5.86B$13.88B$16.44B$1.89B$19.94B$21.07B$4.76B
Net Income
$3.92B$2.39B$6.22B$9.84B$7.07B$13.05B$14.52B$365.0M$17.12B$18.25B$2.45B
EPS (Diluted)
2.040.932.323.822.785.145.710.146.747.280.97
EBITDA
$10.82B$11.95B$13.99B$16.01B$10.18B$17.90B$21.32B$6.91B$25.71B$28.26B$13.03B
Shares Out. (M)
2787.002748.002679.002580.002541.002538.002542.002547.002541.002507.002478.00

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$6.51B$6.09B$7.96B$9.68B$8.05B$8.10B$12.69B$6.84B$13.24B$14.56B$9.55B
Short-Term Investments
$7.83B$2.41B$899.0M$774.0M$0.00$0.00$498.0M$252.0M$447.0M$0.00$100.0M
Total Current Assets
$30.61B$24.77B$25.88B$27.48B$27.76B$30.27B$35.72B$32.17B$38.78B$43.52B$38.94B
Total Assets
$95.38B$87.87B$82.64B$84.40B$91.59B$105.69B$109.16B$106.67B$117.11B$136.87B$132.77B
Total Current Liabilities
$17.20B$18.61B$22.21B$22.22B$27.33B$23.87B$24.24B$25.69B$28.42B$28.33B$28.80B
Long-Term Debt
$24.27B$21.35B$19.81B$22.74B$25.36B$30.69B$28.75B$33.68B$34.46B$46.75B$49.69B
Total Liabilities
$55.07B$53.30B$55.76B$58.40B$66.18B$67.44B$63.10B$69.04B$70.73B$84.20B$87.83B
Stockholders' Equity
$40.09B$34.34B$26.70B$25.91B$25.32B$38.18B$45.99B$37.58B$46.31B$52.61B$44.89B
Retained Earnings
$44.13B$41.35B$42.58B$46.60B$47.36B$53.70B$61.08B$53.90B$63.07B$73.08B$66.22B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$10.38B$6.45B$10.92B$13.44B$10.25B$14.11B$19.09B$13.01B$21.47B$16.47B$18.70B
Capital Expenditure
-$1.61B-$1.89B-$2.62B-$3.47B-$4.43B-$4.45B-$4.39B-$3.86B-$3.37B-$4.11B-$3.96B
Free Cash Flow
$8.76B$4.56B$8.31B$9.97B$5.82B$9.66B$14.71B$9.14B$18.10B$12.36B$14.75B
Investing Cash Flow
-$3.21B$2.68B$4.31B-$2.63B-$9.44B-$16.55B-$4.96B-$14.08B-$7.73B-$13.74B-$28.33B
Financing Cash Flow
-$9.04B-$10.01B-$13.16B-$8.86B-$2.83B$2.59B-$9.12B-$4.81B-$7.03B-$1.92B$1.10B
Issuance of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$384.0M$0.00$0.00$92.0M$494.0M
Repurchase of Stock
-$3.43B-$4.01B-$9.09B-$4.78B-$1.28B-$840.0M$0.00-$1.35B-$1.31B-$5.08B-$3.54B
Net Debt Issuance
-$1.31B-$1.13B$837.0M$1.25B$5.01B$1.63B-$2.25B$4.18B$2.31B$11.38B$12.66B
Stock Based Comp.
$300.0M$312.0M$348.0M$417.0M$441.0M$479.0M$541.0M$645.0M$761.0M$0.00$1.06B
Net Change in Cash
-$2.01B-$423.0M$1.87B$1.97B-$1.77B$14.0M$4.61B-$5.86B$6.41B$1.37B-$8.55B

Dilution Tracker

Shares Outstanding
2467M
5-Year Share Growth
-1.3%
Stock Issuance (TTM)
$494.0M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
2787.002748.002679.002580.002541.002538.002542.002547.002541.002507.002478.00
Change vs Prior %
—-1.4%-2.5%-3.7%-1.5%-0.1%0.2%0.2%-0.2%-1.3%-1.2%
Stock Issuance
$0.00$0.00$0.00$0.00$0.00$0.00$384.0M$0.00$0.00$92.0M$494.0M
Stock Repurchase
-$3.43B-$4.01B-$9.09B-$4.78B-$1.28B-$840.0M$0.00-$1.35B-$1.31B-$5.08B-$3.54B
Stock Based Comp.
$300.0M$312.0M$348.0M$417.0M$441.0M$479.0M$541.0M$645.0M$761.0M$0.00$1.06B

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
64.8%67.8%68.1%69.3%67.2%72.0%70.6%73.2%76.3%72.0%77.0%
Operating Margin %
13.8%16.9%21.1%20.3%13.4%27.1%30.8%4.9%31.5%36.2%16.2%
Net Margin %
9.8%6.0%14.7%25.2%17.0%26.8%24.5%0.6%26.7%28.1%3.6%
EBITDA Margin %
27.2%29.8%33.1%40.9%24.5%36.8%36.0%11.5%40.1%43.5%19.4%
FCF Margin %
22.0%11.4%19.6%25.5%14.0%19.8%24.8%15.2%28.2%19.0%21.9%
ROE %
9.8%7.0%23.3%38.0%27.9%34.2%31.6%1.0%37.0%34.7%5.3%
ROA %
4.1%2.7%7.5%11.7%7.7%12.3%13.3%0.3%14.6%13.3%1.8%
ROIC %
5.9%3.5%9.7%9.4%6.0%13.9%18.5%0.7%19.0%18.3%5.2%
R&D / Revenue %
25.8%25.8%23.1%24.9%32.3%25.1%22.9%50.8%28.0%19.3%43.6%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
0.8%0.8%5.4%-7.5%6.1%17.3%21.7%1.4%6.7%1.2%
Gross Profit
4.9%5.6%5.8%-5.8%2.9%25.7%19.4%5.1%11.3%-4.6%
Operating Income
-27.1%23.6%31.4%-11.3%-30.0%137.9%38.5%-83.8%584.5%16.1%
Net Income
-11.8%-38.9%159.8%58.2%-28.2%84.6%11.3%-97.5%4589.6%6.6%
EPS (Diluted)
30.8%-54.4%149.5%64.7%-27.2%84.9%11.1%-97.5%4714.3%8.0%
Operating Cash Flow
-16.5%-37.9%69.4%23.1%-23.7%37.6%35.3%-31.9%65.1%-23.3%
Free Cash Flow
-22.2%-47.9%82.1%20.0%-41.6%65.9%52.2%-37.8%97.9%-31.7%
R&D Expense
53.1%0.8%-5.7%-0.3%37.8%-8.6%10.6%125.4%-41.2%-30.2%
SG&A Expense
-2.9%0.6%0.3%-6.4%-9.4%9.7%2.8%2.2%2.2%6.2%
Total Assets
-6.2%-7.9%-6.0%2.1%8.5%15.4%3.3%-2.3%9.8%16.9%
Book Value / Share
-8.9%-12.6%-19.1%-2.2%-0.9%50.6%20.3%-18.8%23.9%14.9%
Debt
-5.9%-1.7%2.9%8.9%22.2%3.6%-7.6%13.4%5.5%32.0%
Diluted Shares
-1.9%-1.4%-2.5%-3.7%-1.5%-0.1%0.2%0.2%-0.2%-1.3%

Valuation

P/E (TTM)149.70
10Y Low / Med / High14.42 / 27.12 / 778.71
P/S5.38
10Y Low / Med / High3.61 / 4.47 / 5.69
P/B8.10
10Y Low / Med / High3.85 / 6.11 / 8.59
EV/EBITDA31.16
10Y Low / Med / High10.59 / 14.73 / 44.46
EV/Revenue6.04
10Y Low / Med / High4.06 / 4.87 / 6.14
P/FCF24.55
10Y Low / Med / High13.92 / 22.32 / 33.88

Intrinsic Value Models (per share)

DCF Value
$180.27
Graham Number
$20.09
Cash / Share
$3.89
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
27.1256.4730.3622.5827.9614.8519.36778.7114.7214.42149.70
P/S Ratio
3.883.614.475.694.753.984.744.623.934.065.38
P/B Ratio
3.854.217.078.597.795.086.117.395.445.018.10
EV/EBITDA
15.9513.6414.7315.0021.8812.3214.0844.4610.7710.5931.16
EV/Revenue
4.344.064.876.145.364.535.065.114.324.616.04

Analyst Estimates & Quality

Altman Z-Score
3.96
Safe
Piotroski F-Score
6
Moderate

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$67.22B$69.42B$73.58B
Net Income$6.89B$22.20B$24.48B
EPS$2.77$8.91$9.92
# Analysts (EPS)14148

Dividends

Dividend/Share (TTM)
$3.40
Dividend Yield
2.32%
Frequency
Quarterly

Recent Payments

Ex-DatePay DateAmountFrequency
Sep 15, 2026Oct 7, 2026$0.85Quarterly
Jun 15, 2026Jul 8, 2026$0.85Quarterly
Mar 16, 2026Apr 7, 2026$0.85Quarterly
Dec 15, 2025Jan 8, 2026$0.85Quarterly
Sep 15, 2025Oct 7, 2025$0.81Quarterly
Jun 16, 2025Jul 8, 2025$0.81Quarterly
Mar 17, 2025Apr 7, 2025$0.81Quarterly
Dec 16, 2024Jan 8, 2025$0.81Quarterly
Sep 16, 2024Oct 7, 2024$0.77Quarterly
Jun 17, 2024Jul 8, 2024$0.77Quarterly
Mar 14, 2024Apr 5, 2024$0.77Quarterly
Dec 14, 2023Jan 8, 2024$0.77Quarterly
Sep 14, 2023Oct 6, 2023$0.73Quarterly
Jun 14, 2023Jul 10, 2023$0.73Quarterly
Mar 14, 2023Apr 10, 2023$0.73Quarterly
Dec 14, 2022Jan 9, 2023$0.73Quarterly
Sep 14, 2022Oct 7, 2022$0.69Quarterly
Jun 14, 2022Jul 8, 2022$0.69Quarterly
Mar 14, 2022Apr 7, 2022$0.69Quarterly
Dec 14, 2021Jan 7, 2022$0.69Quarterly

Revenue Segments

By Product

Segment202020212022202320242025
Animal Health segment$4.70B$5.57B$5.55B$5.63B$5.88B$6.35B
Pharmaceutical segment$43.02B$42.75B$52.01B$53.58B$57.40B$58.14B
Other Segments$23.0M$382.0M$1.73B$907.0M$891.0M$515.0M

By Geography

Segment202020212022202320242025
Asia Pacific$2.86B$2.41B$3.61B—$3.06B$2.98B
CHINA$3.62B$4.38B$5.19B—$5.49B$1.94B
EMEA$13.60B$13.34B$14.49B—$14.04B$14.58B
JAPAN$3.38B$2.73B$3.63B—$3.28B$2.71B
Latin America$2.27B$2.21B$2.58B—$3.46B$3.41B
International$1.23B$1.22B$2.57B—$2.56B$2.88B
UNITED STATES$21.03B$22.43B$27.21B—$32.28B$36.51B
Pharmaceutical segment———$53.58B——
Animal Health segment———$5.63B——
Other Segments———$907.0M——